New sulfonamides containing organometallic-acylhydrazones: synthesis, characterisation and biological evaluation as inhibitors of human carbonic anhydrases

References

• (a) Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005 - 2013). Expert Opin Ther Pat 2013;23:681–91;
   PubMed Web of Science ®Google Scholar
  (b) Temperini C, Cecchi A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited-old leads for new applications?. Org Biomol Chem 2008;6:2499–506;
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat 2018;28:709–12;
   PubMed Web of Science ®Google Scholar
  (d) Supuran CT. Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opin Ther Pat 2018;28:713–21;
   PubMed Web of Science ®Google Scholar
  (e) Nocentini A, Supuran CT. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018). Expert Opin Ther Pat 2018;28:729–40;
   PubMed Web of Science ®Google Scholar
  (f) Supuran CT, Capasso C. Biomedical applications of prokaryotic carbonic anhydrases. Expert Opin Ther Pat 2018;28:745–54.
   PubMed Web of Science ®Google Scholar
• (a) Masini E, Carta F, Scozzafava A, Supuran CT. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 2013;23:705–16;
   PubMed Web of Science ®Google Scholar
  (b) Borras J, Scozzafava A, Menabuoni L, et al. Carbonic anhydrase inhibitors: synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties: is the tail more important than the ring?. Bioorg Med Chem 1999;7:2397–06;
   PubMed Web of Science ®Google Scholar
  (c) Capasso C, Supuran CT. An overview of the alpha-, beta-and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria?. J Enzyme Inhib Med Chem 2015;30:325–32.
   PubMed Web of Science ®Google Scholar
• (a) Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat 2013;23:725–35;
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Carbonic anhydrases and metabolism. Metabolites 2018;8:E25;
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov. 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• (a) Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008 - 2013). Expert Opin Ther Pat 2013;23:737–49;
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites 2017;7:E48;
   PubMed Web of Science ®Google Scholar
  (c) Ward C, Langdon SP, Mullen P, et al. New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev 2013;39:171–79;
   PubMed Web of Science ®Google Scholar
  (d) Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg Med Chem Lett 2005;15:3102–08;
   PubMed Web of Science ®Google Scholar
  (e) Casey JR, Morgan PE, Vullo D, et al. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J Med Chem 2004;47:2337–47.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother 2016;16:961–68;
   PubMed Web of Science ®Google Scholar
  (b) Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. J Enzyme Inhib Med Chem 2016;31:894–99.
   PubMed Web of Science ®Google Scholar
• (a) Margheri F, Ceruso M, Carta F, et al. Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium. J Enzyme Inhib Med Chem 2016;31:60–3;
   PubMed Web of Science ®Google Scholar
  (b) Bua S, Di Cesare Mannelli L, Vullo D, et al. Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem 2017;60:1159–70.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors?. J Enzyme Inhib Med Chem 2018;33:485–95;
   PubMed Web of Science ®Google Scholar
  (b) Di Fiore A, Maresca A, Supuran CT, et al. Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors. Chem Commun (Camb) 2012;48:8838–40;
   PubMed Web of Science ®Google Scholar
  (c) Marques SM, Nuti E, Rossello A, et al. Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates. J Med Chem 2008;51:7968–79;
   PubMed Web of Science ®Google Scholar
  (d) Bozdag M, Carta F, Angeli A, et al. Synthesis of N'-phenyl-N-hydroxyureas and investigation of their inhibitory activities on human carbonic anhydrases. Bioorg Chem 2018;78:1–6.
   PubMed Web of Science ®Google Scholar
• (a) Andruh M, Cristurean E, Stefan R, Supuran CT. Carbonic anhydrase inhibitors. Part 6. Novel coordination compounds of Pd(II), Pt(II) and Ni(II) with 6-ethoxybenzothiazole-2-sulfonamide. Rev Roum Chim 1991;36:727–32;
   Web of Science ®Google Scholar
  (b) Luca C, Barboiu M, Supuran CT. Carbonic anhydrase inhibitors. Part 7. Stability constants of complex inhibitors and their mechanism of action. Rev Roum Chim 1991;36:1169–73;
   Web of Science ®Google Scholar
  (c) Supuran CT, Manole G, Andruh M. Carbonic anhydrase inhibitors. Part 11. Coordination compounds of heterocyclic sulfonamides with lanthanides are potent inhibitors of isozymes I and II. J Inorg Biochem 1993;49:97–103;
   PubMed Web of Science ®Google Scholar
  (d) Borras J, Alzuet G, Ferrer S, Supuran CT. Metal complexes of heterocyclic sulfonamides as carbonic anhydrases inhibitors. In Supuran CT, Scozzafava A, Conway J, eds. Carbonic anhydrase – its inhibitors and activators. Boca Raton (FL), USA: CRC Press; 2004:183–207.
   Google Scholar
• (a) Sumalan SL, Casanova J, Alzuet G, et al. Synthesis and characterization of metal(II)-8-quinolinsulfonamidato (sa) complexes (M = Co, Ni, Cu, and Zn). Crystal structure of [Zn(sa)2(NH3)]NH3 complex. Carbonic anhydrase inhibitory properties. J Inorg Biochem 1996;62:31–9;
   PubMed Web of Science ®Google Scholar
  (b) Borràs J, Casanova J, Cristea T, et al. Complexes with biologically active ligands. Part 6 Ni(II) coordination compounds of hydrazine and heterocyclic sulfonamides as inhibitors of the zinc enzyme carbonic anhydrase. Met Based Drugs 1996;3:143–48.
   PubMedGoogle Scholar
• (a) Diaz JR, Fernández Baldo M, Echeverría G, et al. A substituted sulfonamide and its Co (II), Cu (II), and Zn (II) complexes as potential antifungal agents. J Enzyme Inhib Med Chem 2016;31:51–62;
   PubMed Web of Science ®Google Scholar
  (b) Ilies MA, Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors. Part 91. Metal complexes of heterocyclic sulfonamides as potential pharmacological agents in the treatment of gastric acid secretion imbalances. Met Based Drugs 2000;7:57–62;
   PubMedGoogle Scholar
  (c) Mastrolorenzo A, Supuran CT. Antifungal activity of Ag(I) and Zn(II) complexes of sulfacetamide derivatives. Met Based Drugs 2000;7:49–54;
   PubMedGoogle Scholar
  (d) Nakai M, Pan J, Lin KS, et al. Evaluation of 99mTc-sulfonamide and sulfocoumarin derivatives for imaging carbonic anhydrase IX expression. J Inorg Biochem 2018;185:63–70.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT, Scozzafava A, Menabuoni L, et al. Carbonic anhydrase inhibitors part 72 synthesis and antiglaucoma properties of metal complexes of p-fluorobenzolamide. Met Based Drugs 1999;6:67–73;
   PubMedGoogle Scholar
  (b) Supuran CT, Scozzafava A, Briganti F, et al. Carbonic anhydrase inhibitors. Part 55 metal complexes of 1,3,4-thiadiazole-2-sulfonamide derivatives: in vitro inhibition studies with carbonic anhydrase isozymes I, II and IV. Met Based Drugs 1998;5:103–14;
   PubMedGoogle Scholar
  (c) Supuran CT, Scozzafava A, Jitianu A. Carbonic anhydrase inhibitors. Part 54: metal complexes of heterocyclic sulfonamides: a new class of antiglaucoma agents. Met Based Drugs 1997;4:307–15.
   PubMedGoogle Scholar
• (a) Mincione G, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 46 inhibition of carbonic anhydrase isozymes i, ii and iv with trifluoromethylsulfonamide derivatives and their zinc(ii) and copper(ii) complexes. Met Based Drugs 1997;4:27–34;
   PubMedGoogle Scholar
  (b) Scozzafava A, Supuran CT. Complexes with biologically active ligands. part 10 inhibition of carbonic anhydrase isozymes i and ii with metal complexes of imidazo[2,1-b ]-1,3,4-thiadiazole-2-sulfonamide. Met Based Drugs 1997;4:19–26;
   PubMedGoogle Scholar
  (c) Jitianu A, Ilies MA, Briganti F, et al. Complexes with biologically active ligands. Part 9 metal complexes of 5-benzoylamino- and 5-(3-nitrobenzoyl-amino)-1,3,4-thiadiazole-2-sulfonamide as carbonic anhydrase inhibitors. Met Based Drugs 1997;4:1–7.
   PubMedGoogle Scholar
• (a) Supuran CT. Complexes with biologically active ligands. Part 4. Coordination compounds of chlorothiazide with transition metal ions behave as strong carbonic anhydrase inhibitors. Met Based Drugs 1996;3:79–83;
   PubMedGoogle Scholar
  (b) Supuran CT. Metal complexes of 1,3,4-thiadiazole-2,5-disulfonamide are strong dual carbonic anhydrase inhibitors, although the ligand possesses very weak such properties. Met Based Drugs 1995;2:331–36;
   PubMedGoogle Scholar
  (c) Supuran CT. Thienothiopyransulfonamides as complexing agents for the preparation of dual carbonic anhydrase inhibitors. Met Based Drugs 1995;2:327–30.
   PubMedGoogle Scholar
• (a) Can D, Spingler B, Schmutz P, et al. [(Cp-R)M(CO)3] (M = Re or 99mTc) Arylsulfonamide, arylsulfamide, and arylsulfamate conjugates for selective targeting of human carbonic anhydrase IX. Angew Chem Int Ed Engl 2012;51:3354–57;
   PubMed Web of Science ®Google Scholar
  (b) Dilworth JR, Pascu SI, Waghorn PA, et al. Synthesis of sulfonamide conjugates of Cu(II), Ga(III), In(III), Re(V) and Zn(II) complexes: carbonic anhydrase inhibition studies and cellular imaging investigations. Dalton Trans 2015;44:4859–73.
   PubMed Web of Science ®Google Scholar
• Biancalana L, Batchelor LK, Ciancaleoni G, et al. Versatile coordination of acetazolamide to ruthenium(II) p-cymene complexes and preliminary cytotoxicity studies. Dalton Trans 2018;47:9367–84.
   PubMed Web of Science ®Google Scholar
• Heldt J-M, Fischer-Durand N, Salmain M, et al. Preparation and characterization of poly(amidoamine) dendrimers functionalized with a rhenium carbonyl complex and PEG as new IR probes for carbonyl metallo immunoassay. J Organomet Chem 2004;689:4775–82.
   Web of Science ®Google Scholar
• Hromadová M, Salmain M, Sokolová R, et al. Novel redox label for proteins: electron transfer properties of (η5-cyclopentadienyl) tricarbonyl manganese bound to bovine serum albumin. J Organomet Chem 2003;668:17–24.
   Web of Science ®Google Scholar
• Winum JY, Dogné JM, Casini A, et al. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes i, ii, and ix with sulfonamides incorporating hydrazino moieties. J Med Chem 2005;48:2121–5.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Carbonic anhydrases: from biomedical applications of the inhibitors and activators to biotechnological use for CO2 capture. J Enzyme Inhib Med Chem 2013;28:229–30;
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist?. J Enzyme Inhib Med Chem 2016;31:345–60;
   PubMed Web of Science ®Google Scholar
  (c) Alterio V, Di Fiore A, D'Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?. Chem Rev 2012;112:4421–28.
   PubMed Web of Science ®Google Scholar
• Soydan E, Güler A, Bıyık S, et al. Carbonic anhydrase from Apis mellifera: purification and inhibition by pesticides. J Enzyme Inhib Med Chem 2017;32:47–50.
   PubMed Web of Science ®Google Scholar
• Maguene GM, Jakhlal J, Ladyman M, et al. Synthesis and antimycobacterial activity of a series of ferrocenyl derivatives. Eur J Med Chem 2011;46:31–8.
   PubMed Web of Science ®Google Scholar
• Tirkey V, Mishra S, Dash HR, et al. Synthesis, characterization and antibacterial studies of ferrocenyl and cymantrenyl hydrazone compounds. J Organomet Chem 2013;732:122–9.
   Web of Science ®Google Scholar
• Toro P, Suazo C, Acuña A, et al. Cyrhetrenylaniline and new organometallic phenylimines derived from 4- and 5-nitrothiophene: synthesis, characterization, X-Ray structures, electrochemistry and in vitro anti-T. brucei activity. J Organomet Chem 2018;862:13–21.
   Web of Science ®Google Scholar
• Muñoz-Osses M, Godoy F, Fierro A, et al. New organometallic imines of rhenium(i) as potential ligands of GSK-3β: synthesis, characterization and biological studies. Dalt Trans 2018;47:1233–42.
   PubMed Web of Science ®Google Scholar
• Oyarzo J, Acuña A, Klahn H, et al. Isomeric and hybrid ferrocenyl/cyrhetrenyl aldimines: a new family of multifunctional compounds. Dalt Trans 2018;47:1635–49.
   PubMed Web of Science ®Google Scholar
• Arancibia R, Dubar F, Pradines B, et al. Synthesis and antimalarial activities of rhenium bioorganometallics based on the 4-aminoquinoline structure. Bioorg Med Chem 2010;18:8085–91.
   PubMed Web of Science ®Google Scholar
• Arancibia R, Klahn AH, Buono-Core GE, et al. Synthesis, characterization and anti-Trypanosoma cruzi evaluation of ferrocenyl and cyrhetrenyl imines derived from 5-nitrofurane. J Organomet Chem 2011;696:3238–44.
   Web of Science ®Google Scholar
• Arancibia R, Hugo Klahn A, Buono-Core GE, et al. Organometallic Schiff bases derived from 5-nitrothiophene and 5-nitrofurane: synthesis, crystallographic, electrochemical, ESR and antiTrypanosoma cruzi studies. J Organomet Chem 2013;743:49–54.
   Web of Science ®Google Scholar
• Concha C, Quintana C, Klahn AH, et al. Organometallic tosyl hydrazones: synthesis, characterization, crystal structures and in vitro evaluation for anti-Mycobacterium tuberculosis and antiproliferative activities. Polyhedron 2017;131:40–5.
   Web of Science ®Google Scholar
• Casini A, Scozzafava A, Mincione F, et al. Carbonic anhydrase inhibitors: synthesis of water soluble sulfonamides incorporating a 4-sulfamoylphenylmethylthiourea scaffold, with potent intraocular pressure lowering properties. J Enzyme Inhib Med Chem 2002;17:333–3.
   PubMed Web of Science ®Google Scholar
• Karalı N, Akdemir A, Göktaş F, et al. Novel sulfonamide-containing 2-indolinones that selectively inhibit tumor-associated alpha carbonic anhydrases. Bioorg Med Chem 2017;25:3714–8.
   PubMed Web of Science ®Google Scholar
• Chohan ZH, Pervez H, Khan KM, Supuran CT. Organometallic-based antibacterial and antifungal compounds: transition metal complexes of 1,1′-diacetylferrocene-derived thiocarbohydrazone, carbohydrazone, thiosemicarbazone and semicarbazone. J Enzyme Inhib Med Chem 2005;20:81–9.
   PubMed Web of Science ®Google Scholar
• Bolm C, Xiao L, Hintermann L, et al. Synthesis of chiral cyrhetrenes and their application in asymmetric catalysis. Organometallics 2004;23:2362–9.
   Web of Science ®Google Scholar
• Laws DR, Chong D, Nash K, et al. Cymantrene radical cation family: spectral and structural characterization of the half-sandwich analogues of ferrocenium ion. J Am Chem Soc 2008;130:9859–70.
   PubMed Web of Science ®Google Scholar
• Gómez J, Leiva N, Arancibia R, et al. Synthesis, characterization, crystal structures and computational studies on novel cyrhetrenyl hydrazones. J Organomet Chem 2016;819:129–37.
   Web of Science ®Google Scholar
• Quintana C, Klahn AH, Artigas V, et al. Cyrhetrenyl and ferrocenyl 1,3,4-thiadiazole derivatives: synthesis, characterization, crystal structures and in vitro antitubercular activity. Inorg Chem Commun 2015;55:48–50.
   Web of Science ®Google Scholar
• (a) Durgun M, Turkmen H, Ceruso M, Supuran CT. Synthesis of 4-sulfamoylphenyl-benzylamine derivatives with inhibitory activity against human carbonic anhydrase isoforms I, II, IX and XII. Bioorg Med Chem 2016;24:982–8;
   PubMed Web of Science ®Google Scholar
• (b) Durgun M, Turkmen H, Ceruso M, Supuran CT. Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII. Bioorg Med Chem Lett 2015;25:2377–81;
   PubMed Web of Science ®Google Scholar
• (c) Sarikaya B, Ceruso M, Carta F, Supuran CT. Inhibition of carbonic anhydrase isoforms I, II, IX and XII with novel Schiff bases: identification of selective inhibitors for the tumor-associated isoforms over the cytosolic ones. Bioorg Med Chem 2014;22:5883–90.
   PubMed Web of Science ®Google Scholar
• Syakaev VV, Podyachev SN, Buzykin BI, et al. NMR study of conformation and isomerization of aryl- and heteroarylaldehyde 4-tert-butylphenoxyacetylhydrazones. J Mol Struct 2006;788:55–62.
   Web of Science ®Google Scholar
• Ershov AY, Lagoda I V, Yakimovich SI, et al. Tautomerism and conformational isomerism of mercaptoacetylhydrazones of aliphatic and aromatic aldehydes. Russ J Org Chem 2009;45:660–6.
   Web of Science ®Google Scholar
• Patorski P, Wyrzykiewicz E, Bartkowiak G. Synthesis and conformational assignment of N-(E)-stilbenyloxymethylenecarbonyl-substituted hydrazones of acetone and o-(m- and p-) chloro- (nitro-) benzaldehydes by means of 1H and 13C NMR spectroscopy. J Spectrosc 2013;2013:12.
   Web of Science ®Google Scholar
• Gonzaga DTG, Silva FC, da Ferreira VF, et al. Crystal structures of 1-aryl-1H- and 2-aryl-2H-1,2,3-triazolyl hydrazones. Conformational consequences of different classical hydrogen bonds. J Braz Chem Soc 2016;27:2322–33.
   Web of Science ®Google Scholar
• Hamzi I, Barhoumi-Slimi TM, Abidi R. Synthesis, characterization, and conformational study of acylhydrazones of α,β-unsaturated aldehydes. Heteroat Chem 2016;27:139–48.
   Web of Science ®Google Scholar
• Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32.
   PubMed Web of Science ®Google Scholar
• Supuran CT, De Simone G, (eds). Carbonic anhydrases as biocatalysts: from theory to medical and industrial applications. Amsterdam: Elsevier B.V.; 2015.
   Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–181.
   PubMed Web of Science ®Google Scholar
• (a) Scozzafava A, Briganti F, Mincione G, et al. Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. J Med Chem 1999;42:3690–3700;
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT, Scozzafava A, Mastrolorenzo A. Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics. Expert Opin Ther Pat 2001;11:221–59.
   Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.
   PubMed Web of Science ®Google Scholar